The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review

References

• Rodd AL, Ververis K, Karagiannis TC. Current and emerging therapeutics for cutaneous T-cell lymphoma: histone deacetylase inhibitors. Lymphoma. 2012, [290685]. doi:10.1155/2012/290685
   Google Scholar
• Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res. 2016 Jul 28;5. pii: F1000 Faculty Rev-1882. doi: 10.12688/f1000research.8829.1. eCollection 2016. Review. PubMed PMID: 27540476; PubMed Central PMCID: PMC4965697.
   PubMedGoogle Scholar
• Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Alsaleh QA, Nanda A, Al-Ajmi H, et al. Clinicoepidemiological features of mycosis fungoides in Kuwait, 1991–2006. Int J Dermatol. 2010;49(12):1393–1398.
   PubMed Web of Science ®Google Scholar
• Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol. 2007 Jul;143(7):854–859.
   PubMedGoogle Scholar
• Del Guzzo C, Levin A, Dana A, et al. The incidence of cutaneous T-Cell lymphoma in the veteran population. J Invest Dermatol. 2016;136(5):S24.
   PubMed Web of Science ®Google Scholar
• Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013 Nov;149(11):1295–1299.
   PubMed Web of Science ®Google Scholar
• Litvinov IV, Tetzlaff MT, Rahme E, et al. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer. 2015 Jun 15;121(12):1993–2003.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Bonthapally V, Huebner D, et al. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: cutaneous T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:228–240.
   PubMed Web of Science ®Google Scholar
• Bradford PT, Devesa SS, Anderson WF, et al. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009 May 21;113(21):5064–5073.
   PubMed Web of Science ®Google Scholar
• Imam MH, Shenoy PJ, Flowers CR, et al. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013 Apr;54(4):752–759.
   PubMed Web of Science ®Google Scholar
• Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health. 1999 Aug;89(8):1240–1244.
   PubMed Web of Science ®Google Scholar
• Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008 Oct 15;112(8):3082–3087.
   PubMed Web of Science ®Google Scholar
• Jawed SI, Myskowski PL, Horwitz S, et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240–2.
   Web of Science ®Google Scholar
• Hanel W, Briski R, Ross CW, et al. A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and Sezary syndrome. Am J Hematol. 2016 Dec;91(12):E491–e495.
   PubMed Web of Science ®Google Scholar
• Beynon T, Radcliffe E, Child F, et al. What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence. Br J Dermatol. 2014 Mar;170(3):599–608.
   PubMed Web of Science ®Google Scholar
• Beynon T, Selman L, Radcliffe E, et al. We had to change to single beds because I itch in the night’: a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma. Br J Dermatol. 2015 Jul;173(1):83–92.
   PubMed Web of Science ®Google Scholar
• Bouwhuis SA, Gonzalez-Arriaza HL, McEvoy MT, et al. Physical and mental health survey of 20 patients with Sezary syndrome using the medical outcomes study 36-item short-form health survey. J Eur Acad Dermatol Venereol. 2003 Nov;17(6):724–725.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 national cutaneous lymphoma foundation survey. Cancer. 2006 Nov 15;107(10):2504–2511.
   PubMed Web of Science ®Google Scholar
• Salehi M, Azimi Z, Fatemi F, et al. Incidence rate of mycosis fungoides in Isfahan (Iran). J Dermatol. 2010 Aug;37(8):703–707.
   PubMed Web of Science ®Google Scholar
• Talpur R, Wieser I, Wang C, et al. Evaluation of health related questionnaire among mycosis fungoides and lymphomatoid papulosis. Blood. 2015;126(23):5603.
   Web of Science ®Google Scholar
• Porkert S, Lehner-Baumgartner E, Knobler R, et al. J-04. Assessment of QoL, illness perception, and illness behavior in 92 patients with primary cutaneous lymphoma. Presented at the 3rd World Congress of Cutaneous Lymphomas, New York, NY; 2016 Oct 26–28.
   Google Scholar
• Chmielowska E, Studzinski M, Giebel S, et al. Follow-up of patients with mycosis fungoides after interferon alpha2b treatment failure. Postepy Dermatol Alergol. 2015 Apr;32(2):67–72.
   PubMed Web of Science ®Google Scholar
• Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4):311–321.
   PubMedGoogle Scholar
• Straus DJ, Duvic M, Horwitz SM, et al. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol. 2014 Jan;25(1):206–210.
   PubMed Web of Science ®Google Scholar
• Assaf C, Becker JC, Beyer M, et al. Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin–consensus of the lymphoma group of the working group dermatologic oncology. J Dtsch Dermatol Ges. 2013 Apr;11(4):338–347.
   PubMed Web of Science ®Google Scholar
• Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003 Sep 1;98(5):993–1001.
   PubMed Web of Science ®Google Scholar
• Wollina U, Hohaus K, Schonlebe J, et al. Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma: report of three cases. J Cancer Res Clin Oncol. 2003 Jan;129(1):65–69.
   PubMed Web of Science ®Google Scholar
• FDA. Vorinostat PI. [cited 2020 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf
   Google Scholar
• FDA. Romidepsin PI. [cited 2020 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022393lbl.pdf
   Google Scholar
• FDA. Denileukin diftitox PI. [cited 2020 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103767s5094lbl.pdf
   Google Scholar
• FDA. Bexarotene PI. [cited 2020 Jan 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021055s010lbl.pdf
   Google Scholar
• de Masson A, Guitera P, Brice P, et al. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol. 2014 Mar;170(3):720–724.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009 Aug 18;151(4):264–9, w64.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Single technology appraisal: user guide for company evidence submission template. 2015.
   Google Scholar
• Effective Public Health Practice Project. Quality assessment tool for quantitative studies. 2004.
   Google Scholar
• Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012 Aug;51(8):930–934.
   PubMed Web of Science ®Google Scholar
• Wright A, Wijeratne A, Hung T, et al. Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma. J Pain Symptom Manage. 2013 Jan;45(1):114–119.
   PubMed Web of Science ®Google Scholar
• Talpur R, Wieser I, Wang C, et al. Evaluation of health related questionnaire among mycosis fungoides and lymphomatoid papulosis. J Am Acad Dermatol. 2016;74(5):AB117.
   Web of Science ®Google Scholar
• Prince HM, Dummer R, Whittaker S, et al. Patient-reported outcomes and quality of life in patients with cutaneous T cell lymphoma: results from the phase 3 ALCANZA study [conference abstract]. Hematol Oncol. 2017 June;35(Supplement 2):247–248.
   Google Scholar
• Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005 Mar;141(3):325–330.
   PubMed Web of Science ®Google Scholar
• Sampogna F, Frontani M, Baliva G, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol. 2009 Apr;160(4):815–822.
   PubMed Web of Science ®Google Scholar
• Demierre MF, Ferzli P, Miller D. Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis. Arch Dermatol. 2007 May;143(5):659–661.
   PubMedGoogle Scholar
• Eder J, Kammerstatter M, Erhart F, et al. Illness perception in primary cutaneous T-cell lymphomas: what patients believe about their disease. Acta Derm Venereol. 2016 Mar;96(3):381–385.
   PubMed Web of Science ®Google Scholar
• Selman LE, Beynon T, Radcliffe E, et al. ‘We’re all carrying a burden that we’re not sharing’: a qualitative study of the impact of cutaneous T-cell lymphoma on the family. Br J Dermatol. 2015 Jun;172(6):1581–1592.
   PubMed Web of Science ®Google Scholar
• McCann S, Astley E, Huwe J, et al. Poster - caregiver burden and quality of life factors affecting caregivers caring for patients with cutaneous T-cell lymphoma. 2016 [cited 2017 Jun 09]. Available from: http://www.nursinglibrary.org/vhl/handle/10755/621226
   Google Scholar
• Sokolowska-Wojdylo M, Florek A, Zaucha JM, et al. Polish lymphoma research group experience with bexarotene in the treatment of cutaneous T-cell lymphoma. Am J Ther. 2016 May-Jun;23(3):e749–56.
   PubMed Web of Science ®Google Scholar
• Rupoli S, Canafoglia L, Goteri G, et al. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides. Eur J Dermatol. 2016 Jan-Feb;26(1):13–20.
   PubMed Web of Science ®Google Scholar
• Rupoli S, Goteri G, Micucci G, et al. Time to next treatment analysis for early and advanced stages of mycosis fungoides/Sezary syndrome treated with bexarotene and puva in combination [conference abstract]. Haematologica. 2017 June;102(Supplement 2):466–467.
   PubMedGoogle Scholar
• Izu R, Yanguas I, Servitje O, et al. Experience with bexarotene in cutaneous T-cell lymphoma: a collaborative study of the Spanish group of cutaneous lymphoma. J Am Acad Dermatol. 2014;70(5):Suppl.1; AB123.
   Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez-Diez J, et al. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma. Hematology. 2015 Oct;20(9):538–542.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): results from the phase III MAVORIC study. Blood. 2017;130(Suppl 1):817.
   PubMedGoogle Scholar
• Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Jun 06;390(10094):555–566.
   PubMed Web of Science ®Google Scholar
• Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10;28(11):1870–1877.
   PubMed Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811–819.
   PubMed Web of Science ®Google Scholar
• Morris SL, McGovern M, Bayne S, et al. Results of a 5-week schedule of modern total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Aug 01;86(5):936–941.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Scarisbrick JJ, Dummer R, et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL). Blood. 2017;130(Suppl 1):1509.
   Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013 Jan;49(2):386–394.
   PubMed Web of Science ®Google Scholar
• Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012 Nov 20;30(33):4091–4097.
   PubMed Web of Science ®Google Scholar
• Aviles A, Nambo MJ, Neri N, et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sezary syndrome. Cancer Biother Radiopharm. 2007 Dec;22(6):836–840.
   PubMed Web of Science ®Google Scholar
• Duvic M. Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. Clin Adv Hematol Oncol. 2014 Feb;12(2 Suppl 6):10–11.
   Google Scholar
• Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015 Nov 10;33(32):3759–3765.
   PubMed Web of Science ®Google Scholar
• Duvic M, Kim YH, Zinzani PL, et al. Results from a phase I/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed/refractory cutaneous T-cell lymphoma. Clin Cancer Res. 2017 Jul 15;23(14):3552-3556. doi: 10.1158/1078-0432.CCR-16-2064. Epub 2017 Feb 6. PubMed PMID: 28167509; PubMed Central PMCID: PMC5511551.
   Web of Science ®Google Scholar
• Illidge T, Chan C, Counsell N, et al. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Br J Cancer. 2013 Nov 12;109(10):2566–2573.
   PubMed Web of Science ®Google Scholar
• Duvic M, Martin AG, Olsen EA, et al. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar;54(3):514–519.
   PubMed Web of Science ®Google Scholar
• Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19;125(12):1883–1889.
   PubMed Web of Science ®Google Scholar
• Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012 Mar 10;30(8):837–842.
   PubMed Web of Science ®Google Scholar
• Foss F, Duvic M, Lerner A, et al. Clinical efficacy of romidepsin in tumor stage and folliculotropic mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):637–643.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10;28(29):4485–4491.
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 01;109(1):31–39.
   PubMed Web of Science ®Google Scholar
• Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007 Apr 15;13(8):2318–2322.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20;25(21):3109–3115.
   PubMed Web of Science ®Google Scholar
• Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sezary syndrome. Br J Dermatol. 2009 Jun;160(6):1299–1307.
   PubMed Web of Science ®Google Scholar
• Atilla E, Atilla PA, Bozdag SC, et al. Extracorporeal photochemotherapy in mycosis fungoides [Photochimiotherapie extracorporelle dans les mycoses fongiques.]. Transfus Clin Biol. 2017a November;24(4):454–457.
   PubMedGoogle Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 03;119(18):4115–4122.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 May 01;109(9):1799–1803.
   PubMed Web of Science ®Google Scholar
• Cheeley J, Sahn RE, DeLong LK, et al. Acitretin for the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2013 Feb;68(2):247–254.
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015 Feb;72(2):286–292.
   PubMed Web of Science ®Google Scholar
• Lindahl LM, Kamstrup MR, Petersen PM, et al. Total skin electron beam therapy for cutaneous T-cell lymphoma: a nationwide cohort study from Denmark. Acta Oncologica. 2011 Nov 01;50(8):1199–1205.
   PubMed Web of Science ®Google Scholar
• Bates SE, Eisch R, Ling A, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015 Jul;170(1):96–109.
   PubMed Web of Science ®Google Scholar
• Duvic M, Kim YH, Rook AH, et al. Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) and prior treatment with systemic chemotherapy: subanalysis from the pivotal phase 2 study. Blood. 2014;124(21):4451.
   Web of Science ®Google Scholar
• Kim EJ, Kim YH, Rook AH, et al. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015;56(10):2847–2854.
   PubMed Web of Science ®Google Scholar
• Duvic M, Forero-Torres A, Foss, F, et al. Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J Clin Oncol. 2009;27:15_suppl, 8552-8552.
   Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood. 2014 Feb 20;123(8):1159–1166.
   PubMed Web of Science ®Google Scholar
• Martinez-Escala ME, Kuzel TM, Kaplan JB, et al. Durable responses with maintenance dose-sparing regimens of romidepsin in cutaneous T-cell lymphoma. JAMA Oncol. 2016 Jun 01;2(6):790–793.
   PubMed Web of Science ®Google Scholar
• Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome. Arch Dermatol. 2008 Jun;144(6):727–733.
   PubMedGoogle Scholar
• Atilla E, Ataca P, Civriz Bozdag S, et al. Extracorporeal photopheresis for the treatment of mycosis fungoides. Blood. 2015;126(23):5062.
   Web of Science ®Google Scholar
• Coronel-Perez IM, Carrizosa-Esquivel AM, Camacho-Martinez F. [Narrow band UVB therapy in early stage mycosis fungoides. A study of 23 patients]. Actas Dermosifiliogr. 2007 May;98(4):259–264.
   PubMedGoogle Scholar
• Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, et al. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol. 2009 Sep;161(3):660–663.
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Stefoni V, Casadei B, et al. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Ann Hematol. 2014 Nov;93(11):1853–1857.
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Siakantaris MP, Vassilakopoulos TP, et al. PUVA plus interferon alpha2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):354–357.
   PubMed Web of Science ®Google Scholar
• Roberge D, Muanza T, Blake G, et al. Does adjuvant alpha-interferon improve outcome when combined with total skin irradiation for mycosis fungoides? Br J Dermatol. 2007 Jan;156(1):57–61.
   PubMed Web of Science ®Google Scholar
• Hernández Z, Peñate Y, Hernández-Machín B, et al. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands. Int J Dermatol. 2014;53(11):1417–1422.
   PubMed Web of Science ®Google Scholar
• Hoot JW, Wang L, Kho T, et al. The effect of phototherapy on progression to tumors in patients with patch and plaque stage of mycosis fungoides. J Dermatological Treat. 2018 May;29(3):272-276.
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Multicenter phase II trial of temozolomide in mycosis fungoides/Sezary syndrome: correlation with O(6)-methylguanine-DNA methyltransferase and mismatch repair proteins. Clin Cancer Res. 2011 Sep 01;17(17):5748–5754.
   PubMed Web of Science ®Google Scholar
• Hinds GA, Alhariri J, Klein RQ, et al. Treatment of mycosis fungoides with total skin electron beam: response and relapse by ethnicity and sex. Am J Clin Oncol. 2013 Oct;36(5):481–485.
   PubMed Web of Science ®Google Scholar
• Kroeger K, Elsayad K, Moustakis C, et al. Low-dose total skin electron beam therapy for cutaneous lymphoma: minimal risk of acute toxicities. Strahlenther Onkol. 2017 Dec;193(12):1024–1030.
   PubMed Web of Science ®Google Scholar
• Prince HM, Martin AG, Olsen EA, et al. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sezary syndrome. Leuk Lymphoma. 2013 Jan;54(1):69–75.
   PubMed Web of Science ®Google Scholar
• Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):377–384.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410–5417.
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Rozati S, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or Sezarysyndrome: final results show significant clinical activity and suggest correlation with CD30 expression. Blood. 2014;124(21):804.
   Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015 Nov 10;33(32):3750–3758.
   PubMed Web of Science ®Google Scholar
• Dalal MR, Whittaker S, Horwitz S, et al. Phase 3 ALCANZA study of brentuximab vedotin or physician’s choice of methotrexate or bexarotene in CD30-positive cutaneous T-cell lymphoma: number needed to treat analysis. P637. European Hematology Association Annual Congress. June 22–25, 2017; Madrid, Spain.
   Google Scholar
• Mathieu S, Ram-Wolff C, Quéreux G, et al. The French experience of treatment of cutaneous T cell lymphoma with brentuximab vedotin: a series of 32 cases. 3rd world congress of cutaneous lymphoma, New York, NY; 2016. Abstract no: P-04. 2016.
   Google Scholar
• Dummer R, Duvic M, Scarisbrick J, et al. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (mycosis fungoides and Sezary syndrome). Ann Oncol. 2014 Sep;25(9):1807–1812.
   PubMed Web of Science ®Google Scholar
• Anlong L, Girardi M, Parker T, et al. Pralatrexate in cutaneous T cell lymphoma: retrospective experience with and without leucovorin. 3rd world congress of cutaneous lymphoma, New York, NY; 2016. Abstract no: N-03. 2016.
   Google Scholar
• Child F, Ortiz-Romero PL, Alvarez R, et al. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sezary syndrome. Br J Dermatol. 2016 Jul;175(1):80–88.
   PubMed Web of Science ®Google Scholar
• Almazan T, Armstrong R, Kim YH, et al. 380 Determination of molecular remission in patients with mycosis fungoides (MF) and Sezary Syndrome (SS) following allogeneic transplant using high throughput sequencing (HTS). J Invest Dermatol. 2017;137(5):S65.
   Web of Science ®Google Scholar
• de Masson A, Beylot-Barry M, Bouaziz JD, et al. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French society of bone marrow transplantation and French study group on cutaneous lymphomas. Haematologica. 2014 Mar;99(3):527–534.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010 Oct 10;28(29):4492–4499.
   PubMed Web of Science ®Google Scholar
• Hosing C, Bassett R, Dabaja B, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015 Dec;26(12):2490–2495.
   PubMed Web of Science ®Google Scholar
• Lechowicz MJ, Lazarus HM, Carreras J, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014 Nov;49(11):1360–1365.
   PubMed Web of Science ®Google Scholar
• Mehta-Shah N, Teja S, Tao Y, et al. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. Blood. 2017;130(Suppl 1):4597.
   Google Scholar
• Menter T, Medani H, Olavarria E, et al. Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2016 Mar 01;180(6):904–908.
   PubMed Web of Science ®Google Scholar
• Weng W-K, Armstrong R, Arai S, et al. Non-myeloablative allogeneic transplantation resulting in clinical and molecular remission with low non-relapse mortality (NRM) in patients with advanced stage mycosis fungoides (MF) and Sézary syndrome (SS). Blood. 2014;124(21):2544.
   PubMed Web of Science ®Google Scholar
• Turner RM, Spiegelhalter DJ, Smith GC, et al. Bias modelling in evidence synthesis. J R Stat Soc Ser A Stat Soc. 2009 Jan;172(1):21–47.
   PubMedGoogle Scholar
• Porcu P, Hudgens S, Quaglino P, et al. Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial. J Clin Oncol. 2018 May 20;36(15_suppl):7577.
   Web of Science ®Google Scholar